Training

Register now

Location

Boston Medical Center - Crosstown Building
801 Massachusetts Avenue
2nd Floor, RM 2128
Boston, MA

Description

This course comprises the first half of the eight-hour buprenorphine waiver course.

ALL REGISTRANTS MUST COMPLETE THE SECOND FOUR HOURS ONLINE AFTER THIS EVENT. After the event, you will be sent a link to complete the second part of the eight-hour waiver training. You must complete the last four hours within 30 days of this training event and pass the online test, or you will be required to retake the full eight hours of training.

This four hour course prepares physicians, nurse practitioners, and physician assistants to prescribe buprenorphine to treat opioid use disorder in their office, with a focus on the treatment of adolescents and young adults. The course will also fulfill waiver training requirements for providers who do not specialize adolescent or pediatric care. The curriculum includes the science of addiction as a brain disorder, the pharmacology of buprenorphine, and the regulatory requirements around prescribing this medication. In addition to addressing the management of buprenorphine treatment in the general population, particular attention will be devoted to the special considerations involved in treating adolescents and young adults. Attendees will learn to screen patients for treatment with buprenorphine and to manage the medication along with the patient's other medical needs in an office setting such as a primary care clinic. The course fulfills 8 hours of the training needed to obtain a waiver to prescribe buprenorphine. The Drug Addiction Treatment Act of 2000 (DATA 2000) requires physicians to complete 8 hours of approved training in order to be eligible for a waiver, and nurse practitioners and physician assistants to complete 24 hours. Check-in for the course will be from 7:30am am to 8:00 am and the training will run from 8:00 am to 12:00 pm.

Breakfast will be served for this event.

DAY OF Contact: Colleen LaBelle - 617-797-6712.

 This is an in-person training. There will not be an option to attend via webinar.

Intended audience

Physicians (MD, DO), Nurse Practitioners, and Physician Assistants

Objectives

Upon completion of the first 4 hours of training in-person and the second 4 hours of training online, the participants will be able to:

• Have the training required to apply for a waiver to prescribe buprenorphone to their patients with opioid dependence (addiction)
• Identify and assess patients who are appropriate for treatment with buprenorphine
• Have the specific knowledge concerning the use of buprenorphine to manage opioid dependence in the outpatient setting
• Discuss the psychiatric and medical co-morbidities associated with opioid addiction

Sponsored by

Boston Medical Center Grayken Center for Addiction, Massachusetts Department of Public Health, Bureau of Substance Abuse Services (DPH/BSAS)

American Academy of Addiction Psychiatry (AAAP) is the Data 2000 Sponsor for this training

Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA.  The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government

Accreditation information

This program has no commercial support. Faculty and planners have no vested interests and there are no conflicts of interest. There will be no discussion of off label uses of drugs. 

Accreditation

 

In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), the American Academy of PAs (AAPA), American Psychological Association (APA) and Association for Social Work Boards (ASWB) to provide continuing education for the healthcare team.

 Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 4 (four) Interprofessional Continuing Education credits for learning and change.

 

Physician Designation

American Academy of Addiction Psychiatry designates this enduring material for a maximum of 4 (four) AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Designation

This program has been reviewed and is acceptable for up to 4 (four) Nursing Contact Hours.

Pharmacy Designation

This course has been approved for 4 (four) hours of pharmacy continuing education credit. The approval number issued is: ____. (number as been requested from

 

Physician Assistant Designation

American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4 AAPA Category 1 CME credits. Approval is valid until 3/1/2022. PAs should only claim credit commensurate with the extent of their participation. 

 

Method of participation in the activity: To be awarded a maximum of 4 AAPA Category 1 CME credits you must:

1. Review 5 training modules (4 hours) provided in this activity.
2. Earn a passing score of 75% on each of the module’s post-tests.
3. Complete a final evaluation and follow instructions at the end of the course regarding how to retrieve your Certificate of Completion as well as your continuing credit certificate*.

*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.

 

Disclosures:

AAAP's CE program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. In order to resolve any identified Conflicts of Interest, disclosure information from all series planners and speakers is provided during the planning process to ensure resolution of any identified conflicts. The following PCSS-MAT AAAP staff and CPD Committee members have reported that they have no commercial relationships relevant to the content of this activity to disclose: Thomas Penders, MD, Michael Goedde, MD, Kevin Sevarino, MD, Nitigna Desai, MD, Stephen Wyatt, DO, Sanchit Maruti, MD, Kathryn Cates-Wessel, Justina Andonian and Miriam Giles.

 

Disclosure of Unlabeled Medication Use:

Recommendations involving clinical medicine are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.

Register now